Showing 41-50 of 604 results for "".
Dispatches from the 2022 Skin of Color Update
https://practicaldermatology.com/conferences/skin-of-color-update-2022/dispatches-from-the-2022-skin-of-color-update/23822/Co-chair Dr. Andrew F. Alexis shares highlights from the recent meeting.Bipolar Radiofrequency Microneedling for the Treatment of Facial Lipoma: A Case Study
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/bipolar-radiofrequency-microneedling-for-the-treatment-of-facial-lipoma-a-case-study/24001/Clara Barranco, MD, Rachel Murray, DO, Karthik Krishnamurthy, DO, Alexandra Lawlor BS, and Mary Pentel, MDEvolving Perspectives: The Dermatology M&A Market in Today’s Environment
https://practicaldermatology.com/topics/practice-management/evolving-perspectives-the-dermatology-ma-market-in-todays-environment/23945/Halfway through 2023: The trends and emerging insights in the dermatology and aesthetics industries.Photoprotection in Diverse Patient Populations
https://practicaldermatology.com/programs/practical-dermatology/photoprotection-in-diverse-patient-populations/18196/In part one of a three-part podcast series on dermatologic issues facing patients with darker skin tones, Drs. Andrew Alexis, Corey Hartman, and Janiene Luke discuss photoprotection and why it matters for all patients.The Use of Lasers and Energy-Based Devices in Patients with Richly Pigmented Skin
https://practicaldermatology.com/programs/practical-dermatology/the-use-of-lasers-and-energy-based-devices-in-patients-with-richly-pigmented-skin/18199/In the last of a three-part podcast series on dermatologic issues facing patients with darker skin tones, Andrew Alexis, MD, a dermatologist from New York City and the President of the Skin of Color Society, Corey Hartman, MD, a dermatologist in Birmingham, Alabama, and Janiene Luke, MD, a dermatoloTime Is Hair: An Update on the Diagnosis and Treatment of Scarring Alopecias in Patients with Darker Skin Tones
https://practicaldermatology.com/programs/practical-dermatology/time-is-hair-an-update-on-the-diagnosis-and-treatment-of-scarring-alopecia-in-patients-with-darker-skin-tones/18198/In part two of a three-part podcast series on dermatologic issues facing patients with darker skin tones, Dr. Andrew Alexis, a dermatologist from New York City and the President of the Skin of Color Society; Dr. Corey Hartman, a dermatologist in Birmingham, Alabama; and Dr. Janiene Luke, a dermatoloFDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuLaser hair removal in darker skin types, challenges and technological advances for treatment
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-hair-removal-in-darker-skin-types-challenges-and-technological-advances-for-treatment/18800/Andrew Alexis, MD discusses laser hair removal treatment challenges in patients with higher Fitzpatrick skin types, and how recent advances in technology have been able to address these to deliver effective treatment with minimal pain.Make a Profound Impact
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/make-a-profound-impact/18886/Macrene Alexiades, MD, Ph.D, shares her experience with the Profound system, a micro-needling RF device, with real-time temperature feedback mechanism that improves mandibular and submandibular contouring. The device works by stimulating collagen, elastin and hyaluronic acid resulting in a youthfulEffector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/48960/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous ur